The Effect of COVID-19 on Platelet Counts in Persistent and Chronic Adult ITP Patients: A Real-World Study in China

EJHaem Pub Date : 2025-03-29 DOI:10.1002/jha2.70025

Yujiao Zhang, Lei Yang, Zhongping Xu, Xin Zhou

{"title":"The Effect of COVID-19 on Platelet Counts in Persistent and Chronic Adult ITP Patients: A Real-World Study in China","authors":"Yujiao Zhang, Lei Yang, Zhongping Xu, Xin Zhou","doi":"10.1002/jha2.70025","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>While coronavirus disease 2019 (COVID-19)-associated thrombocytopenia is well-documented, its effects on immune thrombocytopenia (ITP) patients remain unclear. This study aimed to investigate the impact of COVID-19 infection on platelet (PLT) dynamics in chronic ITP patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study analyzed 21 persistent and chronic ITP patients before and after mild COVID-19 infection during China's December 2022 reopening, comparing platelet parameter changes with a focus on clinical characteristics of thrombopoietin receptor agonist (TPO-RA) treated patients.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>TPO-RA treated patients demonstrated transient platelet surges peaking at 1 week postinfection, returning to baseline within 2–3 weeks, contrasting sharply with thrombocytopenia patterns in non-ITP populations. This suggests synergistic effects between virus-induced inflammatory cytokines and TPO-RA may drive transient megakaryopoiesis.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These findings underscore infection-related PLT fluctuations in ITP, necessitating monitoring for thrombotic and bleeding risks and TPO-RA dose optimization during infections.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>The authors have confirmed clinical trial registration is not needed for this submission</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70025","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

While coronavirus disease 2019 (COVID-19)-associated thrombocytopenia is well-documented, its effects on immune thrombocytopenia (ITP) patients remain unclear. This study aimed to investigate the impact of COVID-19 infection on platelet (PLT) dynamics in chronic ITP patients.

Methods

This retrospective study analyzed 21 persistent and chronic ITP patients before and after mild COVID-19 infection during China's December 2022 reopening, comparing platelet parameter changes with a focus on clinical characteristics of thrombopoietin receptor agonist (TPO-RA) treated patients.

Results

TPO-RA treated patients demonstrated transient platelet surges peaking at 1 week postinfection, returning to baseline within 2–3 weeks, contrasting sharply with thrombocytopenia patterns in non-ITP populations. This suggests synergistic effects between virus-induced inflammatory cytokines and TPO-RA may drive transient megakaryopoiesis.

Conclusion

These findings underscore infection-related PLT fluctuations in ITP, necessitating monitoring for thrombotic and bleeding risks and TPO-RA dose optimization during infections.

Trial Registration

The authors have confirmed clinical trial registration is not needed for this submission

Abstract Image

查看原文本刊更多论文

COVID-19对持续性和慢性成人ITP患者血小板计数的影响：一项在中国的真实世界研究

虽然冠状病毒病2019 （COVID-19）相关的血小板减少有充分的文献记载，但其对免疫性血小板减少（ITP）患者的影响尚不清楚。本研究旨在探讨COVID-19感染对慢性ITP患者血小板（PLT）动态的影响。方法回顾性分析2022年12月中国重新开放期间21例轻度COVID-19感染前后的持续性和慢性ITP患者，比较血小板参数的变化，重点分析血小板生成素受体激动剂（TPO-RA）治疗患者的临床特征。结果TPO-RA治疗的患者在感染后1周表现出短暂的血小板激增，在2-3周内恢复到基线水平，与非itp人群的血小板减少模式形成鲜明对比。这表明病毒诱导的炎症细胞因子和TPO-RA之间的协同作用可能驱动瞬态巨核生成。结论这些发现强调了ITP中与感染相关的PLT波动，有必要在感染期间监测血栓和出血风险以及TPO-RA剂量优化。试验注册作者已确认该提交不需要临床试验注册

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量